Open AccessBioequivalence and Pharmacokinetic Evaluation of Two Oral Formulations of Regorafenib: An Open-Label, Randomised, Single-Dose, Two-Period, Two-Way Crossover Clinical Trial in Healthy Chinese Volunteers Under Fasting and Fed Conditions
Author(s) -
Qian Zhang,
Zhiqiang Wang,
Jialu Wu,
Zhen Zhou,
Renpeng Zhou,
Wei Hu
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s323169
Subject(s) - bioequivalence , pharmacokinetics , regorafenib , medicine , crossover study , pharmacology , adverse effect , population , dosing , placebo , colorectal cancer , cancer , alternative medicine , environmental health , pathology
Regorafenib is an oral multi-kinase inhibitor approved for the treatment of solid tumours, but the pharmacokinetic profile of regorafenib in the Chinese population is unclear.